†Alpha-1 antitrypsin deficiency is sometimes referred to as just Alpha-1 deficiency.
Learn about product support
Managing Alpha-1 deficiency begins with understanding it.
Alpha-1 antitrypsin circulates in your bloodstream and helps protect the elastic structures of your lungs from an enzyme that can attack normal body tissue. Without enough functional Alpha-1 antitrypsin, lung damage can develop, usually in people between 20 and 50 years of age.
A severe Alpha-1 deficiency can lead to emphysema—a lung condition that causes shortness of breath—with symptoms that can worsen over time.
Alpha-1 deficiency is caused by a genetic mutation that occurs in about 1 in every 3,000 to 5,000 people in the U.S. It’s also the most common genetic cause of emphysema.
If you and your doctor have decided to treat your Alpha-1 deficiency with GLASSIA, begin with the basics on how GLASSIA works—and then explore options for your infusion experience.
The Alpha-1 antitrypsin protein protects the lung tissue by blocking certain enzyme-caused damage. Such damage can lead to severe lung disease, such as emphysema.
Alpha-1 antitrypsin augmentation is chronic maintenance therapy. So, GLASSIA is typically given once every week to increase levels of Alpha-1 antitrypsin in your blood and lungs.
GLASSIA is an intravenous (into a vein) infusion that generally takes about 15 minutes at the recommended dose and maximum infusion rate.
GLASSIA’s flexibility of administration lets you decide where you want to infuse. Talk to your healthcare provider about which administration option works best for you:
‡If self-administration is deemed appropriate, ensure that you receive detailed instructions and adequate training on how to administer at home or other appropriate setting and have demonstrated the ability to independently administer GLASSIA.
We know that living with Alpha-1 deficiency looks different for everyone. We get to know you, understand who you are, and learn what’s important to you—so that we can focus on what you specifically need when it comes to your prescribed Takeda therapy.
The program can cover up to 100% of your out-of-pocket co-pay costs, if you’re eligible. To be eligible for this program, you must:
§To be eligible, you must be enrolled in OnePath and have commercial insurance. Other terms and conditions apply. Call OnePath for more details.
¶IMPORTANT NOTICE: The OnePath Co-Pay Assistance Program (the Program) is not valid for prescriptions eligible to be reimbursed, in whole or in part, by Medicaid, Medicare (including Medicare Part D), Tricare, Medigap, VA, DoD, or other federal or state programs (including any medical or state prescription drug assistance programs). No claim for reimbursement of the out-of-pocket expense amount covered by the Program shall be submitted to any third party payer, whether public or private. The Program cannot be combined with any other rebate/coupon, free trial, or similar offer. Copayment assistance under the Program is not transferable. The Program only applies in the United States, including Puerto Rico and other U.S. territories, and does not apply where prohibited by law, taxed, or restricted. This does not constitute health insurance. Void where use is prohibited by your insurance provider. If your insurance situation changes, you must notify the Program immediately at 1-866-888-0660. Coverage of certain administration charges will not apply for patients residing in states where it is prohibited by law. Takeda reserves the right to rescind, revoke, or amend the Program at any time without notice.
Sign up, and we’ll make sure you get the latest information about Alpha-1 deficiency and GLASSIA.
*Indicates a required field.
What is GLASSIA?
GLASSIA is a medicine containing human Alpha1-Proteinase Inhibitor (Alpha1-PI) that is used to treat adults with lung disease (emphysema) because of severe Alpha1-antitrypsin (Alpha1) deficiency. GLASSIA is not meant to be used as a therapy for lung disease other than severe Alpha1 deficiency. Effects of GLASSIA on worsening lung function and emphysema progression have not been proven in clinical trials. Long-term effects of Alpha1 replacement and maintenance therapy have not been studied.
GLASSIA is a medicine used to treat adults with lung disease (emphysema) caused by severe Alpha1-antitrypsin (AAT) deficiency. GLASSIA increases the levels of the AAT protein in your blood and lungs ... . It is not known if increasing AAT levels with GLASSIA affects worsening lung function or emphysema progression. Long-term effects of AAT therapy with GLASSIA have not been studied. Please see full Indication and Limitations of Use below.
What is the most important information I need to know about GLASSIA?